Want to see CH:NOVN full AI Analyst Report?
NOVN Stock Chart & Stats
CHF118.82
-CHF1.10(-1.10%)
At close: 4:00 PM EST
CHF118.82
-CHF1.10(-1.10%)
Day’s Range― - ―
52-Week RangeCHF91.56 - CHF131.00
Previous CloseN/A
Volume858.75K
Average Volume (3M)2.71M
Market Cap
CHF229.19B
Enterprise ValueCHF275.93K
Total Cash (Recent Filing)CHF7.71B
Total Debt (Recent Filing)CHF49.15B
Price to Earnings (P/E)23.3
Beta1.01
Next Earnings
Oct 27, 2026EPS Estimate
1.83Next Dividend Ex-DateN/A
Dividend Yield2.95%
Share Statistics
EPS (TTM)6.59
Shares Outstanding2,034,819,500
10 Day Avg. Volume2,438,245
30 Day Avg. Volume2,709,021
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF127.18Price Target Upside7.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)8.75
Revenue Forecast (FY)CHF56.85B
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation & High MarginsHigh reported margins and ~ $16B trailing free cash flow provide durable funding for R&D, launches, and shareholder returns. Robust cash generation cushions against revenue volatility, supports continued investment in priority franchises, and preserves strategic flexibility despite a modest FCF decline.
Multiple High‑growth Launches & Diversified Growth DriversA broad set of priority brands (Kisqali, Scemblix, LEQVIO, PLUVICTO, Kesimpta) showing sustained double‑digit growth reduces single‑product dependence. Diversified, accelerating launches improve probability of replacing lost exclusivity and support multi‑region revenue resilience over the medium term.
De‑risking Pipeline And Regulatory ProgressConcrete regulatory milestones (accelerated FDA submission, meaningful OS readouts) and visible gene‑therapy commercialization plans materially de‑risk future approvals. Successful readouts/submissions would expand addressable markets and underpin multi‑year revenue upside from late‑stage assets.
Bears Say
Rising Financial LeverageDebt increasing to roughly $49B and debt/equity ~1.22x meaningfully raises leverage. Higher indebtedness reduces financial flexibility for M&A or cushioning operational setbacks, increases refinancing and interest sensitivity, and amplifies downside if cash flows or launch trajectories weaken.
Significant Generic Erosion (Entresto)Entresto's loss of exclusivity created a material revenue and comparability headwind (~$800M in the Q3 base), compressing near‑term sales and margins. Sustained generic pressure requires successful new launches to offset recurring revenue declines, raising replacement risk over the medium term.
Execution & Regulatory Dependence; Margin Phasing RiskReliance on multiple pivotal readouts and regulatory decisions concentrates binary execution risk: delayed or negative outcomes would materially affect medium‑term growth. Additionally, one‑time phasing and Avidity‑related costs that boosted Q2 margins will reverse, creating potential H2 margin pressure.
Novartis AG News
NOVN FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was CHF91.56 and its highest was CHF131.00 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF229.19B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Oct 27, 2026 which is in 96 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Jul 21, 2026. The company reported CHF1.96 earnings per share for the quarter, beating the consensus estimate of CHF1.763 by CHF0.197.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of CHF3.7 which represents an annual dividend yield of 2.95%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.83.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.96 in its last earnings report, beating expectations of CHF1.763. Following the earnings report the stock price went up 1.982%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in CH:NOVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOVN Stock 12 Month Forecast
Average Price Target
CHF127.18
▲(7.04% Upside)